{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:17:03Z","timestamp":1793423823067,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ejca.2021.11.016","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T17:51:58Z","timestamp":1640281918000},"page":"65-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Hypersensitivity to Pegylated E.coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group"],"prefix":"10.1016","volume":"162","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2816-2610","authenticated-orcid":false,"given":"Leiah J.","family":"Brigitha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Fiocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Pieters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3902-3694","authenticated-orcid":false,"given":"Birgitte K.","family":"Albertsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Escherich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5309-3031","authenticated-orcid":false,"given":"Elixabet","family":"Lopez-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0401-2100","authenticated-orcid":false,"given":"Veerle","family":"Mondelaers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2167-4368","authenticated-orcid":false,"given":"Ajay","family":"Vora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Vrooman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjeld","family":"Schmiegelow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M.","family":"van der Sluis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 4","key":"10.1016\/j.ejca.2021.11.016_bib1","first-page":"111","article-title":"L-Asparaginase: discovery and development as a tumor-inhibitory agent","volume":"65","author":"Broome","year":"1981","journal-title":"Cancer Treat Rep"},{"issue":"2","key":"10.1016\/j.ejca.2021.11.016_bib2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1040-8428(98)00015-8","article-title":"Use of L-asparaginase in childhood ALL","volume":"28","author":"Muller","year":"1998","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"10.1016\/j.ejca.2021.11.016_bib3","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/cncr.25489","article-title":"L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase","volume":"117","author":"Pieters","year":"2011","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2021.11.016_bib4","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","article-title":"A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study","volume":"99","author":"Avramis","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ejca.2021.11.016_bib5","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1016\/S1470-2045(16)30035-3","article-title":"Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus","volume":"17","author":"Schmiegelow","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2021.11.016_bib6","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3324\/haematol.2015.137380","article-title":"Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation","volume":"101","author":"van der Sluis","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2021.11.016_bib7","series-title":"Allergic-like reactions to asparaginase: atypical allergies without asparaginase inactivation","author":"Kloos","year":"2016"},{"issue":"13","key":"10.1016\/j.ejca.2021.11.016_bib8","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.2217\/fon-2016-0005","article-title":"Immunology of infusion reactions in the treatment of patients with acute lymphoblastic leukemia","volume":"12","author":"Asselin","year":"2016","journal-title":"Future Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2021.11.016_bib9","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1200\/JCO.19.03024","article-title":"Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the children's Oncology group","volume":"38","author":"Gupta","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2021.11.016_bib10","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2012.43.2070","volume":"31","author":"vrooman","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.11.016_bib11","series-title":"Relapse risk following truncation of PEG-asparaginase in childhood acute lymphoblastic leukemia","author":"H\u00f8jfeldt","year":"2020"},{"issue":"4","key":"10.1016\/j.ejca.2021.11.016_bib12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00043426-200404000-00002","article-title":"Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: children's Cancer Group Study CCG-1961","volume":"26","author":"Panosyan","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2021.11.016_bib13","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/pbc.23041","article-title":"Five-year single-center study of asparaginase therapy within the ALL-BFM 2000 trial","volume":"57","author":"Schrey","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2021.11.016_bib14","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1182\/blood.V99.8.2734","article-title":"Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial","volume":"99","author":"Duval","year":"2002","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ejca.2021.11.016_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27083","article-title":"Efficacy and safety of recombinant E. coli asparaginase in children with previously untreated acute lymphoblastic leukemia: a randomized multicenter study of the Dutch Childhood Oncology Group","volume":"65","author":"van der Sluis","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"13","key":"10.1016\/j.ejca.2021.11.016_bib17","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1182\/blood-2013-10-534347","article-title":"A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia","volume":"123","author":"Tong","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2021.11.016_bib19","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.01877","article-title":"Intermittent versus continuous PEG-asparaginase to reduce asparaginase-associated toxicities: a NOPHO ALL2008 randomized study","author":"Albertsen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2021.11.016_bib20","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S1470-2045(15)00363-0","article-title":"Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial","volume":"16","author":"Place","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.11.016_bib23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Contr Clin Trials"},{"issue":"2","key":"10.1016\/j.ejca.2021.11.016_bib24","first-page":"119","article-title":"Approximate is better than \u201cexact\u201d for interval estimation of binomial proportions","volume":"52","author":"Agresti","year":"1998","journal-title":"Am Stat"},{"issue":"5","key":"10.1016\/j.ejca.2021.11.016_bib25","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.csda.2011.05.009","article-title":"Meta-analysis of time-to-event outcomes using a hazard-based approach: comparison with other models, robustness and meta-regression","volume":"56","author":"Fiocco","year":"2012","journal-title":"Comput Stat Data Anal"},{"key":"10.1016\/j.ejca.2021.11.016_bib26","series-title":"R: a language and environment for statistical computing","year":"2013"},{"issue":"1","key":"10.1016\/j.ejca.2021.11.016_bib27","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/FTD.0000000000000472","article-title":"Therapeutic drug monitoring of asparaginase activity-method comparison of MAAT and AHA test used in the international AIEOP-BFM ALL 2009 trial","volume":"40","author":"Lanvers-Kaminsky","year":"2018","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10.1016\/j.ejca.2021.11.016_bib28","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/pbc.22225","article-title":"Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia","volume":"54","author":"Vrooman","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ejca.2021.11.016_bib29","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0021-9258(19)42886-X","article-title":"Substrate binding and intersubunit interactions in L-asparaginase","volume":"249","author":"Shifrin","year":"1973","journal-title":"J Biol Chem"},{"issue":"1\u20132","key":"10.1016\/j.ejca.2021.11.016_bib30","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0022-1759(00)00182-4","article-title":"ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia","volume":"239","author":"Wang","year":"2000","journal-title":"J Immunol Methods"},{"issue":"june","key":"10.1016\/j.ejca.2021.11.016_bib31","first-page":"1","article-title":"Antibodies predict pegaspargase allergic reactions and failure of rechallenge","author":"Yiwei Liu","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2021.11.016_bib32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cncr.22739","article-title":"Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients","volume":"110","author":"Armstrong","year":"2007","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2021.11.016_bib33","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/bjh.16254","article-title":"Acute lymphoblastic leukaemia patients treated with PEGasparaginase develop antibodies to PEG and the succinate linker","volume":"189","author":"Kloos","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2021.11.016_bib34","series-title":"Severe pegaspargase hypersensitivity reaction rates (grade >\/=3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials","first-page":"1","author":"Burke","year":"2017"},{"issue":"1","key":"10.1016\/j.ejca.2021.11.016_bib35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/pbc.26200","article-title":"Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: a meta-analysis and systematic review","volume":"64","author":"Hasan","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ejca.2021.11.016_bib36","series-title":"Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia","first-page":"1176","author":"Avramis","year":"2006"},{"issue":"5","key":"10.1016\/j.ejca.2021.11.016_bib37","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/mpo.10096","article-title":"Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase","volume":"38","author":"Albertsen","year":"2002","journal-title":"Med Pediatr Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2021.11.016_bib38","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.3109\/10428194.2010.494316","article-title":"Silent hypersensitivity to Escherichia coli asparaginase in children with acute lymphoblastic leukemia","volume":"51","author":"Strullu","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.ejca.2021.11.016_bib39","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1200\/JCO.19.02292","article-title":"Individualized asparaginase dosing in childhood acute lymphoblastic leukemia","volume":"38","author":"Kloos","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2021.11.016_bib40","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pbc.25319","article-title":"PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol","volume":"62","author":"Henriksen","year":"2015","journal-title":"Pediatr Blood Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921012260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921012260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:35:01Z","timestamp":1760733301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921012260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":36,"alternative-id":["S0959804921012260"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.11.016","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypersensitivity to Pegylated E.coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}